Morgantown, WV, United States
Morgantown, WV, United States

Time filter

Source Type

News Article | May 4, 2017
Site: www.prnewswire.com

MORGANTOWN, W.Va. and KALAMAZOO, Mich., May 4, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") and Proteos, Inc. ("Proteos") announced today that they have entered into a joint co-marketing agreement.  This mutual partnership allows Protea to combine Proteos' p...


News Article | October 19, 2016
Site: globenewswire.com

MORGANTOWN, W.Va., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today the use of the Company’s proprietary LAESI technology to provide rapid profiling of a bacteria’s resistance to antibiotics. The results were recently published in the International Edition of the Journal Angewandte Chemie, by Dr. H. Li, and Prof. Akos Vertes, Department of Chemistry, The George Washington University. The publication’s title is “Molecular Imaging of Growth, Metabolism, and Antibiotic Inhibition in Bacterial Colonies by Laser Ablation Electrospray Ionization Mass Spectrometry (LAESI).” “We are pleased to see the unique capabilities of LAESI technology applied to antibiotic research,” stated Steve Turner, Protea’s CEO. He added, “In this study, LAESI was shown to help reveal molecular information that has the potential to significantly contribute to new antibiotic research and development.” Professor Vertes commented, “With the emergence of multidrug resistant microbial strains and bacterial pathogens, the need for rapid and accurate testing of antibiotic susceptibility is increasing. Understanding microbial metabolism and its inhibition by antibiotics is important for developing new treatments of bacterial infections. These results indicate the potential of LAESI-MSI to study antibiotic diffusion patterns in tissues qualitatively and quantitatively, and to explore complex bacterial interactions.” Characterizing existing and emerging microbial strains and their interactions with antimicrobial agents currently relies on time-consuming methods with limited ability to provide molecular information. Assessing the metabolic adaptation of microbial colonies requires the capability to perform non-targeted molecular imaging in a native environment. LAESI technology enabled the direct analysis and imaging of numerous metabolites and lipids in both two and three dimensions. LAESI technology was invented in the laboratory of Professor Akos Vertes and exclusively licensed to Protea. LAESI is new bioanalytical technology that directly detects and maps molecules in diverse biological samples without the need to apply chemicals or introduce tags or tracers. LAESI enables both 2D and 3D molecular imaging, and results are available in seconds to minutes. About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. The company provides proprietary molecular information services to its clients in the pharmaceutical and life science industries. Forward-Looking Statements; This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. For more Information:   Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA Phone:  304.292.2226      Fax:  304.292.7101 Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.


News Article | January 10, 2017
Site: globenewswire.com

MORGANTOWN, W.Va., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today that the Company has entered into a co-marketing agreement with MatTek Corporation (“MatTek”), which allows Protea to include MatTek’s human cell based in vitro tissue models with Protea’s proprietary molecular imaging services. “By combining the human tissue models with mass spectrometry imaging workflows, researchers will be able to visualize specific compounds in highly - controlled experimental conditions using human cell derived, in vitro models,” stated Haddon Goodman, Vice President, Corporate Development.  He added, “For example, utilizing MatTek’s EpiDerm™ skin model, we can map the distribution of topical compounds, while also visualizing the distribution of biomolecules present in the tissue. These experiments determine if a compound is penetrating the skin without using a tag or marker on the compound, which are commonly needed for visualization using traditional techniques.” The in vitro models are easier to source, much more reproducible and more humane as compared to human or animal skin tissues. MatTek is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models.  The outstanding relevance and reproducibility of EpiDerm and EpiOcular, MatTek’s corneal tissue model, produced impressive results in international multi-laboratory pre-validation and validation studies, leading to acceptance by OECD as test methods for skin and ocular irritation and corrosion testing. The companies plan to jointly present data at the 76th annual Society for Investigative Dermatology conference on April 26-29 in Portland, Oregon.  This work will highlight the benefit of integrating human cell-based tissue models with Protea’s mass spectrometry imaging workflows. About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing proprietary, bioanalytical workflows to the pharmaceutical and life science industries. "Molecular information", the generation and bioinformatic processing of very large data sets, is obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. About MatTek Corporation:  MatTek Corporation is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models. MatTek’s skin, ocular, intestinal and respiratory tissue models are used in regulatory toxicology (OECD, EU guidelines) and product development programs to address toxicology and efficacy concerns throughout the cosmetic/personal care, household product, chemical, and pharmaceutical industries. Forward-Looking Statements; This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.


Patent
Protea Biosciences Group and Yale University | Date: 2016-10-07

A method of differentiating benign melanocytic nevi from malignant melanomas is disclosed. The method generally includes subjecting a skin lesion sample from a patient to mass spectrometry to obtain a mass spectrometry protein profile. This profile is compared to mass spectrometry protein profiles of reference samples, which include known normal, benign melanocytic nevi, and/or malignant melanomas. Classification of the skin lesion sample as a benign melanocytic nevus or a malignant melanoma is based on similarities and difference between the mass spectrometry protein profiles.


Patent
Protea Biosciences Group | Date: 2012-06-25

Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R_(1 )is independently selected from (CH_(2))_(0-9)CH_(3), R_(2 )is selected from the group consisting of H and (CH_(2))_(0-5)CH_(3), Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.


Patent
Protea Biosciences Group | Date: 2012-06-25

Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R_(1 )is independently selected from (CH_(2))_(0-9)CH_(3), R_(2 )is selected from the group consisting of H and (CH_(2))_(0-5)CH_(3), Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.


Patent
Protea Biosciences Group | Date: 2014-06-23

A compound may generally comprise the formula: wherein R_(1 )is independently selected from C_(2)-C_(10 )alkyl or substituted alkyl, R_(2 )is independently selected from the group consisting of H and C_(1)-C_(6 )alkyl or substituted alkyl, X is selected from the group consisting of NH and O, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.


Patent
Protea Biosciences Group and George Washington University | Date: 2014-08-26

In various embodiments, a device may generally comprise a remote ablation chamber comprising an inlet and an outlet, a laser to deposit energy into a sample in the chamber to ablate the sample and generate ablation products in the chamber, a transport device in fluid communication with the outlet, an ionization source to ionize the ablation products to produce ions, and a mass spectrometer having an ion transfer inlet to capture the ions. The ablation products or the ions may be transported in a fluid stream from the ablation chamber through the transport device. The distance from the outlet of the ablation chamber to the ion transfer inlet may be from 1 cm to 10 m. Methods of making and using the same are also described.


News Article | January 18, 2017
Site: globenewswire.com

MORGANTOWN, W.Va., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today that the Company has signed a renewal of its collaboration with California-based Protein Metrics Inc. for further applications development of their advanced analytical software for Protea’s molecular information services. “By combining our high-resolution mass spectrometry molecular data with the analytical power of Protein Metrics software, we are delivering more comprehensive molecular information to researchers who are developing complex biotherapeutics,” commented David Halverson, Protea’s President and Chief Business Officer.  He added, “This collaboration will empower researchers with bioinformatics tools to facilitate the analysis of the structure of therapeutic proteins, including their disulfide linkages, glycoforms and other structural components.” Protea and Protein Metrics plan to create co-authored presentations this year to highlight the benefit of the combined analytical workflows with data processing and reporting capabilities. Eric Carlson, President and CEO of Protein Metrics, commented “We are delighted to renew our partnership with Protea Biosciences.  It’s exciting to contribute to the quality analysis and reports that Protea provides to their many clients.  Thanks to the input from Protea during the first stage of our collaboration, our latest releases include many new features that allow analysts to review all of their data on a common platform and share it with collaborators and customers in a clear, consistent fashion.” About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing proprietary, bioanalytical workflows to the pharmaceutical and life science industries. "Molecular information", the generation and bioinformatic processing of very large data sets, is obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. About Protein Metrics Inc. Protein Metrics has deep experience in protein identification software.  With its current software products and multiple new products to be released shortly, Protein Metrics delivers tools to increase productivity and analytical quality, reduce costs and accelerate development timelines. Protein Metrics is a dynamic software company serving biopharmaceutical development professionals and proteomics researchers. The Company focuses on the analysis of mass spectrometric and other analytical data to provide detailed, efficient characterization of proteins and glycans. Over the past ten+ years, hardware for mass spectrometry has improved dramatically, and the company’s aim is to allow researchers to convert the new wealth of data from these instruments into to knowledge by providing innovative software that makes analytical results more accurate, more complete, and easier to achieve.  The company is headquartered in San Carlos, California.  For more information, visit www.proteinmetrics.com. Forward-Looking Statements; This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. For more Information:          Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA Phone: 304.292.2226 Fax: 304.292.7101 Details of Protein Metrics biopharma suite can be found at www.proteinmetrics.com Protea is a registered trademarks of Protea Biosciences Group, Inc.


News Article | January 10, 2017
Site: globenewswire.com

MORGANTOWN, W.Va., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today that the Company has entered into a co-marketing agreement with MatTek Corporation (“MatTek”), which allows Protea to include MatTek’s human cell based in vitro tissue models with Protea’s proprietary molecular imaging services. “By combining the human tissue models with mass spectrometry imaging workflows, researchers will be able to visualize specific compounds in highly - controlled experimental conditions using human cell derived, in vitro models,” stated Haddon Goodman, Vice President, Corporate Development.  He added, “For example, utilizing MatTek’s EpiDerm™ skin model, we can map the distribution of topical compounds, while also visualizing the distribution of biomolecules present in the tissue. These experiments determine if a compound is penetrating the skin without using a tag or marker on the compound, which are commonly needed for visualization using traditional techniques.” The in vitro models are easier to source, much more reproducible and more humane as compared to human or animal skin tissues. MatTek is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models.  The outstanding relevance and reproducibility of EpiDerm and EpiOcular, MatTek’s corneal tissue model, produced impressive results in international multi-laboratory pre-validation and validation studies, leading to acceptance by OECD as test methods for skin and ocular irritation and corrosion testing. The companies plan to jointly present data at the 76th annual Society for Investigative Dermatology conference on April 26-29 in Portland, Oregon.  This work will highlight the benefit of integrating human cell-based tissue models with Protea’s mass spectrometry imaging workflows. About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing proprietary, bioanalytical workflows to the pharmaceutical and life science industries. "Molecular information", the generation and bioinformatic processing of very large data sets, is obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. About MatTek Corporation:  MatTek Corporation is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models. MatTek’s skin, ocular, intestinal and respiratory tissue models are used in regulatory toxicology (OECD, EU guidelines) and product development programs to address toxicology and efficacy concerns throughout the cosmetic/personal care, household product, chemical, and pharmaceutical industries. Forward-Looking Statements; This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.

Loading Protea Biosciences Group collaborators
Loading Protea Biosciences Group collaborators